|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Classification of diabetic retinopathy and diabetic macular edema显示文摘The global incidence and prevalence of diabetes mellitus(DM)have reached epidemic proportions.Estimates indicate that more than 360 million people will be affected by DM by 2030.All of these individuals will be at risk of developing diabetic retinopathy(DR).It is extremely important to categorize,classify and stage the severity of DR in order to establish adequate therapy.With proper management more than 90%of cases of visual loss can be prevented.The purpose of the current paper is to review the classification of DR with a special emphasis on the International Clinical Disease Severity Scale for DR.This new classification is simple to use,easy to remember and based on scientific evidence.It does not require specialized examinations such as optical coherence tomography or fluorescein angiography.It is based on clinical examination and applying the Early Treatment of Diabetic Retinopathy Study 4:2:1 rule. | Lihteh Wu Priscilla Fernandez-Loaiza Johanna Sauma Erick Hernandez-Bogantes Marissé Masis | 2013 | World Journal of Diabetes2013，4，6： | 6 |
| 2 | Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema显示文摘 | J. Fernando Arevalo Juan G. Sanchez Lihteh Wu Mauricio Maia Arturo A. Alezzandrini Miguel Brito Sergio Bonafonte Silvio Lujan Manuel Diaz-Llopis Natalia Restrepo Francisco J. Rodríguez Patricia Udaondo-Mirete | 2009 | Ophthalmology2009，，8： | 2 |
| 3 | Twelve-month safety of intravitreal injections of bevacizumab (Avastin?): results of the Pan-American Collaborative Retina Study Group (PACORES)显示文摘 | Lihteh Wu María A. Martínez-Castellanos Hugo Quiroz-Mercado J. Fernando Arevalo María H. Berrocal Michel E. Farah Mauricio Maia José A. Roca Francisco J. Rodriguez | 2008 | Graefe’s Archive for Clinical and Experimental Ophthalmology2008，，1： | 1 |
| 4 | Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema显示文摘 | J. Fernando Arevalo Juan G. Sanchez Lihteh Wu Mauricio Maia Arturo A. Alezzandrini Miguel Brito Sergio Bonafonte Silvio Lujan Manuel Diaz-Llopis Natalia Restrepo Francisco J. Rodríguez Patricia Udaondo-Mirete | 2009 | Ophthalmology2009，，8： | 1 |
| 5 | Twelve-month safety of intravitreal injections of bevacizumab (Avastin?): results of the Pan-American Collaborative Retina Study Group (PACORES)显示文摘 | Lihteh Wu María A. Martínez-Castellanos Hugo Quiroz-Mercado J. Fernando Arevalo María H. Berrocal Michel E. Farah Mauricio Maia José A. Roca Francisco J. Rodriguez | 2008 | Graefe’s Archive for Clinical and Experimental Ophthalmology2008，，1： | 1 |
| 6 | Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions显示文摘 | Lihteh WU Fernando Arevalo Maria H | | 0，，： | 1 |
| 7 | Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up显示文摘 | J. Fernando Arevalo Juan G. Sanchez Jans Fromow-Guerra Lihteh Wu Maria H. Berrocal Michel E. Farah Jose Cardillo Francisco J. Rodríguez | 2009 | Graefe’s Archive for Clinical and Experimental Ophthalmology2009，，6： | 1 |
| 8 | Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up显示文摘 | J. Fernando Arevalo Juan G. Sanchez Jans Fromow-Guerra Lihteh Wu Maria H. Berrocal Michel E. Farah Jose Cardillo Francisco J. Rodríguez | 2009 | Graefe’s Archive for Clinical and Experimental Ophthalmology2009，，6： | 1 |
| 9 | Twelve-month safety of intravitreal injections of bevacizumab ( Avastin (R) ) : results of the Pan-American Collaborative Retina Study Group(PACORES) 显示文摘 | LIHTEH WU MARIA A MARTINEZ C | 2008 | Graefes Arch Clin Exp Ophthalmol2008，246，1： | 1 |
| 10 | Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema显示文摘 | J. Fernando Arevalo Rafael A. Garcia-Amaris Jose A. Roca Juan G. Sanchez Lihteh Wu Maria H. Berrocal Mauricio Maia | 2007 | Journal of Cataract & Refractive Surgery2007，，12： | 1 |
| 11 | Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group显示文摘 | Lihteh Wu J. Fernando Arevalo Erick Hernandez-Bogantes José Roca | 2012 | International Ophthalmology2012，，3： | 1 |
| 12 | Subthreshold laser systems:a narrative review of the current status and advancements for retinal diseases显示文摘Background and Objective:Subthreshold laser therapy has emerged as a therapeutic alternative to traditional laser photocoagulation for certain ophthalmic diseases including central serous chorioretinopathy(CSCR),diabetic macular edema(DME),macular edema secondary to branch retinal vein occlusion(BRVO),and age-related macular degeneration(AMD).The objective of this paper is to review and discuss the clinical applications of subthreshold laser and the mechanisms of different subthreshold laser techniques including subthreshold micropulse laser(SMPL),selective retina therapy(SRT),subthreshold nanosecond laser(SNL),endpoint management(EpM),and transpupillary thermotherapy(TTT).Methods:A narrative review of English literature and publicly available information published before November 2021 from literature databases and computerized texts.We discuss the currently available subthreshold laser systems and the advancements made to perform different subthreshold laser techniques for various ophthalmic diseases.We highlight various clinical studies and therapeutic techniques that have been conducted to further understand the effectiveness of subthreshold laser in the clinical setting.We conclude the article by covering emerging subthreshold laser systems that are currently being developed for future clinical use.The PubMed database was utilized for peer-reviewed articles and pertinent information on subthreshold systems was cited from publicly available online websites covering specific systems.Key Content and Findings:Various subthreshold laser systems have been developed to treat certain retinal diseases.Several systems are currently in development for future clinical applications.Conclusions:While conventional laser photocoagulation has been effective in treating various retinal diseases,subthreshold laser systems aim to provide a therapeutic effect without visible signs of damage to the underlying tissue.This technology may be particularly effective in treating macular disorders.Further clinical studies are needed to evaluate their role in the management of retinal diseases. | Joshua Ong Amrish Selvam Dmitrii SMaltsev Xinyuan Zhang Lihteh Wu Jay Chhablani | 2022 | Annals of Eye Science2022，，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员